TBPH missed EPS expectations by 16.08%
May 09, 2025, 10:35 AM
0.00%
What does TBPH do
Theravance Biopharma, based in Grand Cayman, focuses on developing respiratory medicines and has 99 employees; its key product, YUPELRI, treats COPD. The company is also developing Ampreloxetine for neurogenic orthostatic hypotension and TD-8954 for gastrointestinal motility disorders.
Theravance Biopharma (TBPH) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Theravance Biopharma's actual EPS was -$0.27, missing the estimate of -$0.23 per share, resulting in a -16.08% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.